Breaking barriers: supporting hematopoietic stem cell transplant program through collaborative radiation therapy service from a physically distant center

• Published in: Journal of Egyptian National Cancer Institute 2024-05, Vol.36 (1), p.17-7
• Main Authors: Pandit, Subhas, Sapkota, Simit, Adhikari, Abish, Karki, Prakriti, Shrestha, Roshani, Jha, Deepak Suman, Prajapati, Rajan
• Format: Article
• Language: English
• Subjects: Anemia; Aplastic anemia; Cancer; Chemotherapy; Civil service; Conditioning regimen; Cyclophosphamide; Cytomegalovirus; Dosimetry; Drug resistance; Graft versus host disease; Health aspects; Hematology; Hematopoietic stem cell transplant; Hematopoietic stem cells; Leukemia; Low- and middle-income country; Low-dose total body irradiation; Oncology, Experimental; Patients; Pediatrics; Radiation; Radiation therapy; Radiotherapy; Stem cell transplantation; Stem cells; Transplantation
• ISSN: 1110-0362; 2589-0409
• DOI: 10.1186/s43046-024-00221-7

Background Total body irradiation (TBI) for hematopoietic stem cell transplant (HSCT) has certain distinct advantages, such as uniform dose distribution and lack of drug resistance, but it is not widely available in resource-constrained settings. To overcome the limitations of in-house radiotherapy services in hematology centers, we evaluated the feasibility of conducting HSCT programs in coordination with two physically distant centers using a reduced-intensity TBI protocol. Methods Thirty-two patients with a median age of 20.5 years were included in the study. Fifteen patients were diagnosed with aplastic anemia, 10 patients with acute myeloid leukemia (AML), 3 patients with acute lymphocytic leukemia (ALL), and 4 patients with other hematological conditions. Conditioning regimens used were fludarabine plus cyclophosphamide in 29 cases, fludarabine-cytarabine ATG in 2 cases, and busulfan plus fludarabine in 1 case. The TBI dose was 3 Gy in 28 cases and 2 Gy in 4 cases. Patients were followed monthly after TBI, and the major toxicities were recorded. Results The median follow-up was 22 months. The most common acute complication was acute graft-versus-host disease (GVHD), which occurred in 15.6% of patients. The major late complications were chronic GVHD (9.3%), Cytomegalovirus (CMV) infection (34.3%), and CMV-induced secondary graft failure (6.2%). Seventy-five percent of patients were alive, 21.9% were dead, and 1 patient was lost to follow-up. Conclusions HSCT based on TBI is feasible even if the center lacks a radiotherapy facility by coordinating with a remote radiotherapy facility. without compromising the patient's outcome.